semaglutide cardiovascular risk Wegovy lowers cardiovascular risk for adults with obesity at risk for heart disease

GLP-1 receptor agonists can reduce the risk of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist semaglutide can also reduce cardiovascular risk in pts with overweight or obesity

25.51

★★★★☆4.8 (126)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials | Cardiovascular Diabetology

27.36

★★★★★4.9 (98)

Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes

26.37

★★★★★5.0 (157)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials | Cardiovascular Diabetology

28.54

★★★★★4.7 (84)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

20.81

★★★★★4.9 (203)

Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss

27.19

★★★★★5.0 (176)

We've recommended semaglutide (Wegovy) on the NHS to protect heart patients from a second heart attack or stroke. Here's what you need to know: https://www.nice.org.uk/news/articles/semaglutide-injection-to-help-prevent-heart-attacks-and-strokes

29.17

★★★★★4.8 (132)